American College of Allergy, Asthma and Immunology | …
Beta-lactam antibiotic skin testing and oral challengeFrom the ACAAI 2015 Drug Allergy and Anaphylaxis CommitteeBACKROUND: Beta-lactam antibiotics (penicillins, semi-synthetic derivatives, and cephalosporins) are a leading cause of drug allergies in the United States. Patients at elevated risk for IgE mediated (allergic/anaphylactic) reaction to penicillin and penicillin-like drugs can undergo immediate hypersensitivity skin testing to assess or rule out risk for IgE mediated reaction; this testing, if performed with reagents that include penicillin along with major and minor penicillin determinants, is associated with excellent negative predictive value. PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5CZXJuc3RlaW48L0F1dGhvcj48WWVhcj4yMDA4PC9ZZWFy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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5CZXJuc3RlaW48L0F1dGhvcj48WWVhcj4yMDA4PC9ZZWFy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ADDIN EN.CITE.DATA (1-3)Cephalosporins differ from penicillin in the presence of a dihydrothiazine instead of a thiazoladine ring; both possess a beta-lactam ring that participates in covalent binding to carrier proteins and can be immunogenic. There is clear evidence that clinical cross-reactivity to cephalosporins occurs in some patients with IgE-mediated potential to penicillin. The risk of cross- (anaphylactic) reaction from cephalosporins in "penicillin allergic" patients has been estimated at 0-10.5% and varies according to the ‘generation’ of cephalosporin; its precise incidence is unknown. Unlike evaluation of IgE mediated sensitivity to penicillin (which can be ruled out by lack of cutaneous wheal/flare reaction to Pen G and penicilloyl polylysine conjugate, with/without minor determinant mixture), the negative predictive value of skin tests for cephalosporin or semi-synthetic penicillins has not been established, and skin testing with these drugs has not been validated. Nonetheless, the committee recommends that this testing may be carried out in properly selected patients using published non-irritating skin test concentrations. PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5CZXJuc3RlaW48L0F1dGhvcj48WWVhcj4yMDA4PC9ZZWFy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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5CZXJuc3RlaW48L0F1dGhvcj48WWVhcj4yMDA4PC9ZZWFy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ADDIN EN.CITE.DATA (1, 2)The 2008 Allergy Diagnostic and the 2010 Drug Allergy Practice Parameters PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Kb2ludCBUYXNrIEZvcmNlIG9uIFByYWN0aWNlPC9BdXRo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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Kb2ludCBUYXNrIEZvcmNlIG9uIFByYWN0aWNlPC9BdXRo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ADDIN EN.CITE.DATA (2)describe four scenarios: A patient with history of penicillin allergy who requires treatment with penicillin. A patient with history of penicillin allergy who requires treatment with a cephalosporin. A patient with history of cephalosporin allergy who requires treatment with penicillin. A patient with history of cephalosporin allergy who requires treatment with a cephalosporinPURPOSE: To confirm an allergy to a penicillin, cephalosporin and/or other ?-lactam antibioticPOLICY: MD must be in the vicinity for antibiotic skin testing to be performed.===============================================================================Penicillin administration to a patient with a history of PCN allergyPhysician Instructions for penicillin skin testing This protocol will serve as a guideline for penicillin skin testing in patients reporting history of adverse drug reaction to penicillin or a penicillin-like drug (e.g., ampicillin or amoxicillin). The committee carefully considered the agents used, concentration, amount injected, and the method and timing of the reading of the drug tests and the positive and negative controls. Realizing that various publications and clinicians vary in many of these details, the committee is suggesting that this protocol be used to standardize testing among allergists. 1. Perform history and physical examination2. If indicated (i.e. an IgE-mediated adverse drug reaction remains in the differential diagnosis), proceed with penicillin skin testing.3. Prick or percutaneous testing is done first with the reagents listed below. 4. If the prick test is negative, it is followed by the intradermal skin test injecting 0.02 - 0.03 ml using the same reagents.5. Reagents for prick and intradermal (see guidelines on reconstitution described in the “Nursing Instructions” section): a.Negative Control: Sodium chloride solution without preservativeb.Penicillin G 10,000 U/ml (a minor determinant) c.Pre PEN (benzylpenicilloyl polylysine) full strength (major determinant)d. Ampicillin 20 mg/ml for prick and ID testing, PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5CbGFuY2E8L0F1dGhvcj48WWVhcj4yMDA5PC9ZZWFyPjxS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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5CbGFuY2E8L0F1dGhvcj48WWVhcj4yMDA5PC9ZZWFyPjxS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ADDIN EN.CITE.DATA (4, 5) to be considered for inclusion when:Prior reaction was to amoxicillin/ ampicillin or a semi-synthetic penicillin.Patient history is unclear regarding the beta lactam drug associated with past reaction, and the patient requires treatment with amoxicillin/ ampicillin or a semi-synthetic penicillin either immediately or predictably in the futuree. Minor Determinant Mixture (may be used if available; however, minor determinant mixture has not been approved by the FDA) f.Positive Control: HistaminePercutaneous: histamine base 6 mg/ml (histamine dihydrochloride 10 mg/ml)Intradermal: histamine base 0.1 mg/ml (histamine phosphate 0.275 mg/ml)6. A positive test is defined as wheal size equal to or greater than 3 mm diameter with equivalent or greater erythema (flare) compared to the saline control done at the same time.7. The antibiotic testing agents and controls will be read at 15 minutesGraded dose or test dose challenge when PCN skin testing is negative It is recommended that the physician administer a beta-lactam test dose with either penicillin or amoxicillin, based on patient circumstances, after a negative skin test, particularly when skin testing with a minor determinant mixture has not been performed. While some of the earlier studies suggested that an oral challenge was not needed based upon the small percentage of reactions to a subsequent oral challenge, most recent studies have included an oral challenge and the committee feels that this is a safer and more complete method of evaluation. PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5HcmVlbjwvQXV0aG9yPjxZZWFyPjE5Nzc8L1llYXI+PFJl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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5HcmVlbjwvQXV0aG9yPjxZZWFyPjE5Nzc8L1llYXI+PFJl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ADDIN EN.CITE.DATA (6, 7)The determination to challenge with penicillin or amoxicillin/ampicillin may be based on the patient’s history and/or the drug that may need to be administered immediately or prescribed in the future.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NYWN5PC9BdXRob3I+PFllYXI+MjAxNDwvWWVhcj48UmVj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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NYWN5PC9BdXRob3I+PFllYXI+MjAxNDwvWWVhcj48UmVj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ADDIN EN.CITE.DATA (8)?Patients should be observed as long as severe exposure-related reactions are anticipated. This recommendation depends on the type of previous drug reaction, the drug under investigation, and the patient’s individual condition. While the majority of Committee members advocate 60 minutes of observation following the final oral provocation dose PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NYWN5PC9BdXRob3I+PFllYXI+MjAxNDwvWWVhcj48UmVj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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NYWN5PC9BdXRob3I+PFllYXI+MjAxNDwvWWVhcj48UmVj
TnVtPjc8L1JlY051bT48RGlzcGxheVRleHQ+KDgpPC9EaXNwbGF5VGV4dD48cmVjb3JkPjxyZWMt
bnVtYmVyPjc8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJk
cGQ1ZXZ6enpzenJyNGVzcnd0eDB0ZmdzdHR4enAycGZwNXQiIHRpbWVzdGFtcD0iMTQyNjYzMDM0
MCI+Nzwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUi
PjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+TWFjeSwgRS48L2F1
dGhvcj48YXV0aG9yPkNvbnRyZXJhcywgUi48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRv
cnM+PGF1dGgtYWRkcmVzcz5Tb3V0aGVybiBDYWxpZm9ybmlhIFBlcm1hbmVudGUgTWVkaWNhbCBH
cm91cCwgRGVwYXJ0bWVudCBvZiBBbGxlcmd5LCBTYW4gRGllZ28gTWVkaWNhbCBDZW50ZXIsIFNh
biBEaWVnbywgQ2FsaWYuIEVsZWN0cm9uaWMgYWRkcmVzczogZXJpYy5tLm1hY3lAa3Aub3JnLiYj
eEQ7S2Fpc2VyIFBlcm1hbmVudGUgSGVhbHRoIENhcmUgUHJvZ3JhbSwgRGVwYXJ0bWVudCBvZiBS
ZXNlYXJjaCBhbmQgRXZhbHVhdGlvbiwgUGFzYWRlbmEsIENhbGlmLjwvYXV0aC1hZGRyZXNzPjx0
aXRsZXM+PHRpdGxlPkhlYWx0aCBjYXJlIHVzZSBhbmQgc2VyaW91cyBpbmZlY3Rpb24gcHJldmFs
ZW5jZSBhc3NvY2lhdGVkIHdpdGggcGVuaWNpbGxpbiAmcXVvdDthbGxlcmd5JnF1b3Q7IGluIGhv
c3BpdGFsaXplZCBwYXRpZW50czogQSBjb2hvcnQgc3R1ZHk8L3RpdGxlPjxzZWNvbmRhcnktdGl0
bGU+SiBBbGxlcmd5IENsaW4gSW1tdW5vbDwvc2Vjb25kYXJ5LXRpdGxlPjxhbHQtdGl0bGU+VGhl
IEpvdXJuYWwgb2YgYWxsZXJneSBhbmQgY2xpbmljYWwgaW1tdW5vbG9neTwvYWx0LXRpdGxlPjwv
dGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkogQWxsZXJneSBDbGluIEltbXVub2w8L2Z1
bGwtdGl0bGU+PGFiYnItMT5UaGUgSm91cm5hbCBvZiBhbGxlcmd5IGFuZCBjbGluaWNhbCBpbW11
bm9sb2d5PC9hYmJyLTE+PC9wZXJpb2RpY2FsPjxhbHQtcGVyaW9kaWNhbD48ZnVsbC10aXRsZT5K
IEFsbGVyZ3kgQ2xpbiBJbW11bm9sPC9mdWxsLXRpdGxlPjxhYmJyLTE+VGhlIEpvdXJuYWwgb2Yg
YWxsZXJneSBhbmQgY2xpbmljYWwgaW1tdW5vbG9neTwvYWJici0xPjwvYWx0LXBlcmlvZGljYWw+
PHBhZ2VzPjc5MC02PC9wYWdlcz48dm9sdW1lPjEzMzwvdm9sdW1lPjxudW1iZXI+MzwvbnVtYmVy
PjxrZXl3b3Jkcz48a2V5d29yZD5BZHVsdDwva2V5d29yZD48a2V5d29yZD5BZ2VkPC9rZXl3b3Jk
PjxrZXl3b3JkPkJhY3RlcmlhbCBJbmZlY3Rpb25zLyplcGlkZW1pb2xvZ3k8L2tleXdvcmQ+PGtl
eXdvcmQ+Q29ob3J0IFN0dWRpZXM8L2tleXdvcmQ+PGtleXdvcmQ+RGVsaXZlcnkgb2YgSGVhbHRo
IENhcmUvKnV0aWxpemF0aW9uPC9rZXl3b3JkPjxrZXl3b3JkPkRydWcgSHlwZXJzZW5zaXRpdml0
eS8qY29tcGxpY2F0aW9uczwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdv
cmQ+SGVhbHRoIENhcmUgQ29zdHM8L2tleXdvcmQ+PGtleXdvcmQ+SG9zcGl0YWxpemF0aW9uPC9r
ZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5MZW5ndGggb2YgU3RheTwv
a2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3b3JkPk1pZGRsZSBBZ2VkPC9rZXl3
b3JkPjxrZXl3b3JkPlBlbmljaWxsaW5zLyphZHZlcnNlIGVmZmVjdHM8L2tleXdvcmQ+PGtleXdv
cmQ+UHJldmFsZW5jZTwva2V5d29yZD48a2V5d29yZD5SZXRyb3NwZWN0aXZlIFN0dWRpZXM8L2tl
eXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAxNDwveWVhcj48cHViLWRhdGVzPjxkYXRl
Pk1hcjwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjEwOTctNjgyNSAoRWxlY3Ryb25p
YykmI3hEOzAwOTEtNjc0OSAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MjQxODg5NzY8
L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmNiaS5u
bG0ubmloLmdvdi9wdWJtZWQvMjQxODg5NzY8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGVs
ZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjEwMTYvai5qYWNpLjIwMTMuMDkuMDIxPC9lbGVjdHJv
bmljLXJlc291cmNlLW51bT48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPn==
ADDIN EN.CITE.DATA (8), some judge 30 minutes to be adequate for many patients. For this reason, we encourage the allergist to tailor the observation time from 30 to 60 minutes, as they deem most appropriate. A commonly used protocol is the administration of full dose oral beta lactam with monitoring for 30-60 minutes, but an alternative and more cautious protocol may be used that entails a “test dose” (e.g, 1/10-? full oral dose), observation for 30 minutes, followed by the remaining or full oral dose with monitoring for 30-60 minutes. ADDIN EN.CITE <EndNote><Cite><Author>Hypersensitivity</Author><Year>2009</Year><RecNum>54</RecNum><DisplayText>(9)</DisplayText><record><rec-number>54</rec-number><foreign-keys><key app="EN" db-id="dpd5evzzzszrr4esrwtx0tfgsttxzp2pfp5t" timestamp="1431201287">54</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Provocation Tests in Drug Hypersensitivity</author></authors></contributors><titles><title>Drug Hypersensitivity</title><secondary-title>Immunology and Allergy Clinics of North America</secondary-title></titles><volume>29</volume><number>3</number><dates><year>2009</year></dates><publisher>W.B. Saunders Company</publisher><urls></urls></record></Cite></EndNote>(9) Penicillin induction of tolerance (desensitization) when PCN skin testing is positive: Induction of drug tolerance (desensitization) is the progressive administration of an allergenic substance to render effector cells less reactive. This procedure typically is completed over several hours, and the typical starting dose is in the microgram range. The procedure can be performed via oral, intravenous, or subcutaneous routes. The details of conduction this procedure is beyond the scope of this skin testing protocol and the physician is referred to published protocols that can be followed. PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Kb2ludCBUYXNrIEZvcmNlIG9uIFByYWN0aWNlPC9BdXRo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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Kb2ludCBUYXNrIEZvcmNlIG9uIFByYWN0aWNlPC9BdXRo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ADDIN EN.CITE.DATA (2)===============================================================================Cephalosporin administration to a patient with a history of PCN allergy: Unlike evaluation of IgE mediated sensitivity to penicillin (which can be confirmed by demonstration of cutaneous wheal/flare reaction to Pen G, penicilloyl polylysine conjugate, and/or a minor determinant mixture), reagents that would permit performance of cutaneous tests for cephalosporin sensitivity have not been validated. PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5LZWxrYXI8L0F1dGhvcj48WWVhcj4yMDAxPC9ZZWFyPjxS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==
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5LZWxrYXI8L0F1dGhvcj48WWVhcj4yMDAxPC9ZZWFyPjxS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==
ADDIN EN.CITE.DATA (10, 11) Recent data and common impressions among physicians imply that the overwhelming majority of "penicillin allergic" patients can tolerate cephalosporins safely. Despite this, however, severe anaphylactic reactions, including fatalities, have followed administration of cephalosporins to such individuals PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Kb2ludCBUYXNrIEZvcmNlIG9uIFByYWN0aWNlPC9BdXRo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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Kb2ludCBUYXNrIEZvcmNlIG9uIFByYWN0aWNlPC9BdXRo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ADDIN EN.CITE.DATA (2). The committee recognizes that the clinician has several options when facing this situation. The preferred (#1) protocol discussed below is PCN skin testing which is followed by an oral challenge to PCN/Amoxicillin. An alternative option (#2) is skin testing to the cephalosporin (in a non-irritating concentration) that will be used for treatment, followed by either a graded challenge (if skin testing is negative) or by desensitization to cephalosporin (if the skin testing is positive). If this approach is chosen, follow the protocol outlined below under “Administration of cephalosporin to a patient with a history of cephalosporin allergy”. A final option (#3) is to administer the cephalosporin directly under observation. This last option is recommended only in the absence of severe and/or recent penicillin allergic reaction. Option #1 skin testing and oral challenge A. When PCN skin testing and challenge are negativeThe committee recommends that penicillin skin testing be performed in the same manner as described under the above section “Penicillin administration to a patient with a history of PCN allergy”. If the penicillin skin testing is negative, a test dose challenge should be completed using PCN or amoxicillin as above discussed. If there is no adverse reaction, the patient can safely take the cephalosporin. It should be noted that some committee members would omit the test dose challenge and directly administer the cephalosporin. B. When PCN skin testing or challenge is positive:When the patient has positive skin testing or challenge, consensus does not currently exist for management of these penicillin allergic patients, and some are prescribed cephalosporins despite a definite and low (but difficult to quantitate) risk of severe reaction. There are a number of possible choices for treatment as described below. Which option is chosen will be will be at the discretion of the treating physician who has explained the potential for benefit relative to the potential for harm, and has invited the patient to participate in the medical decision making process by expressing their values and preferences.a. Use an alternative non-beta lactam antibiotic. b. When a cephalosporin is clearly indicated, desensitization is an option. c. When a cephalosporin is clearly indicated, administer by graded challenge. CEPHALOSPORIN GRADED DOSE CHALLENGE PROTOCOL The committee offers this protocol as an example, but recognizes that this is not evidence basedTimeCefuroxime Dosage(or alternative agent)9:00 AM25 mg (1/10 dose and wait 30 minutes)9:30 AM250 mg (give 9/10 or full dose and wait 30 minutes10:30 AMENDNote: Dosage amounts and schedule may vary based on degree of suspected sensitivity. ADDIN EN.CITE <EndNote><Cite><Author>Iammatteo</Author><Year>2014</Year><RecNum>63</RecNum><DisplayText>(12)</DisplayText><record><rec-number>63</rec-number><foreign-keys><key app="EN" db-id="dpd5evzzzszrr4esrwtx0tfgsttxzp2pfp5t" timestamp="1432226754">63</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Iammatteo, M.</author><author>Blumenthal, K. G.</author><author>Saff, R.</author><author>Long, A. A.</author><author>Banerji, A.</author></authors></contributors><auth-address>Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Mass. Electronic address: miammatteo@.
Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Mass.</auth-address><titles><title>Safety and outcomes of test doses for the evaluation of adverse drug reactions: a 5-year retrospective review</title><secondary-title>J Allergy Clin Immunol Pract</secondary-title><alt-title>The journal of allergy and clinical immunology. In practice</alt-title></titles><periodical><full-title>J Allergy Clin Immunol Pract</full-title><abbr-1>The journal of allergy and clinical immunology. In practice</abbr-1></periodical><alt-periodical><full-title>J Allergy Clin Immunol Pract</full-title><abbr-1>The journal of allergy and clinical immunology. In practice</abbr-1></alt-periodical><pages>768-74</pages><volume>2</volume><number>6</number><dates><year>2014</year><pub-dates><date>Nov-Dec</date></pub-dates></dates><isbn>2213-2201 (Electronic)</isbn><accession-num>25439369</accession-num><urls><related-urls><url>;(12)The following algorithm taken from the JTF of PP 2010 Drug Allergy PP PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Kb2ludCBUYXNrIEZvcmNlIG9uIFByYWN0aWNlPC9BdXRo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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Kb2ludCBUYXNrIEZvcmNlIG9uIFByYWN0aWNlPC9BdXRo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ADDIN EN.CITE.DATA (2) may be used to assist in the decision-making process: ===============================================================================Administration of penicillin to a patient with a history of cephalosporin allergyFor the case of a patient with a history of cephalosporin allergy who requires treatment with penicillin, it is recommended that the patient have penicillin skin testing with or without an oral challenge, and if negative, the penicillin can be administered; if the penicillin skin test is positive, the patient should be desensitized to the mittee recommended option: Follow the same protocol for penicillin testing and graded dose/test dose challenge as outline in “Penicillin administration to a patient with a history of PCN allergy” described in the first section of this protocol.==============================================================================Administration of cephalosporin to a patient with a history of cephalosporin allergy Note: These recommendations are based upon expert opinion and are not evidence basedThe physicians has the option of 1) Skin testing and subsequent graded dose challenge to the cephalosporin that will be used for treatment 2) performing a graded or test dose challenge to the new cephalosporin after insuring that the two cephalosporin do not share the same R-side chains. This will require accurate identification of the cephalosporin causing the previous allergic reaction. 3) Desensitizing to the new cephalosporin drug. The committee recommends following the # 1 option.# 1 option: Skin testing and graded dose challengeIn general, the concentration used for cephalosporin skin testing is a 10-fold dilution of the standard intravenous concentration, for both percutaneous and intradermal skin testing. See Table 18 for non-irritating concentrations for drug testing.1. Complete cephalosporin skin testing using a non-irritating concentration of the selected cephalosporin. Use these guidelines when selecting a cephalosporin for testing:a. If the specific cephalosporin responsible for the adverse reaction is unknown, use a third generation cephalosporin, e.g., cefuroxime for which both an IV preparation for skin testing and an oral agent for graded dose challenge is available b. If the specific cephalosporin responsible for the adverse reaction is known and an alternative cephalosporin is appropriate for treatment, select a drug that does not share the same R1- or R2-side chains as the cephalosporin that caused the allergic reaction (see Tables 16 and 17 below). c. If the specific cephalosporin responsible for the adverse reaction is known but the preferred or required drug does share one or both of the R1- or R2-side chains, perform skin testing with the drug that is to be administered. d. It is not recommended to skin test to the same cephalosporin that caused the allergic reaction.2. Skin testing procedure for cephalosporin drug: a. Prick test using the concentration listed in Table 18 or, if not listed, using a 10-fold dilution of the standard intravenous concentrationb. Perform intradermal testing using the same concentration as used in 3(a) aboveA. When cephalosporin skin testing is negative:Conduct an oral graded challenge using the cephalosporin that is to be administered following the protocol outlined above under “Cephalosporin administration to a patient with a history of PCN allergy.” If administering a cephalosporin agent that is identical to the one that caused the allergic reaction or shares one or more R- side chains, a more gradual graded challenge may be appropriate, based upon the clinical history and setting.B. When cephalosporin skin testing is positive: 1. Use an alternative non-beta lactam2. Perform desensitization to the cephalosporin===============================================================================The following reference tables are reproduced from the 2010 Drug Allergy Practice ParameterReference tables of β-lactam antibiotics classified according to R1- and R2- side chains.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Kb2ludCBUYXNrIEZvcmNlIG9uIFByYWN0aWNlPC9BdXRo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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Kb2ludCBUYXNrIEZvcmNlIG9uIFByYWN0aWNlPC9BdXRo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ADDIN EN.CITE.DATA (2) Table 3 (Modified from Pichihera ME 2014 ADDIN EN.CITE <EndNote><Cite><Author>Pichichero</Author><Year>2014</Year><RecNum>56</RecNum><DisplayText>(13)</DisplayText><record><rec-number>56</rec-number><foreign-keys><key app="EN" db-id="dpd5evzzzszrr4esrwtx0tfgsttxzp2pfp5t" timestamp="1431827434">56</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Pichichero, M. E.</author><author>Zagursky, R.</author></authors></contributors><auth-address>Rochester General Hospital Research Institute, Rochester, New York. Electronic address: Michael.Pichichero@.
Rochester General Hospital Research Institute, Rochester, New York.</auth-address><titles><title>Penicillin and cephalosporin allergy</title><secondary-title>Ann Allergy Asthma Immunol</secondary-title></titles><periodical><full-title>Ann Allergy Asthma Immunol</full-title><abbr-1>Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology</abbr-1></periodical><pages>404-12</pages><volume>112</volume><number>5</number><keywords><keyword>Anaphylaxis/epidemiology</keyword><keyword>Anti-Bacterial Agents/*adverse effects/therapeutic use</keyword><keyword>Cephalosporins/*adverse effects/chemistry/therapeutic use</keyword><keyword>Cross Reactions/immunology</keyword><keyword>*Drug Hypersensitivity/diagnosis/drug therapy/etiology</keyword><keyword>Humans</keyword><keyword>Penicillins/*adverse effects/chemistry/therapeutic use</keyword><keyword>Practice Guidelines as Topic</keyword><keyword>Skin Tests</keyword></keywords><dates><year>2014</year><pub-dates><date>May</date></pub-dates></dates><isbn>1534-4436 (Electronic)
1081-1206 (Linking)</isbn><accession-num>24767695</accession-num><urls><related-urls><url>;(13)Cephalosporin drugs with similar R1 side-chain structuresGroup I Group II Group III Group IV Group V Group VI Group VII Group VIIIIdentical CefaclorCephaloglycin LoracarbefCephalexinIdenticalCefadroxil Cefatrizine CefprozilIdenticalCefdaloxime CefdinirIdentical Cefepime CefteramCeftiolene Cefditoren CefetametIdenticalCephaloridine CephalothinCefoxitinIdenticalCefozopran CefclidineSimilarCeftobiproleIdentical Cefazolin CeftezoleDissimilarCefazedoneCefbuperazone CefmetazoleCefminox CefotetanSimilarCefmenoximeCe?uprenamCefoperazoneCefamandoleCefodizimeCefpiramideCefonicidCefoselisLess similarCefsulodinCefotaximeCeftaroline fosamilCefuroximeCefpiromeCephacetrileCefpodoximeCephapirinCeftizoximeCephradineCeftriaxoneFlomoxefCefquinomeMoxalactamSimilarCe?ximeCeftazidimeLess similarCeftibutenCefcapeneaThis grouping contains a benzylmethanamine core except for cefamandole and cefonicid, which contains a core of benzylmethanol.bThis grouping contains a 4-(aminomethyl)phenol core.cThis grouping contains a (E)-2-aminothiazole-4-carbaldehyde oxime core.dThis grouping contains a (E)-2-aminothiazole-4-carbaldehyde O-methyl oxime core except for ce?xime, which contains an attached formic acid to O-methyl oxime; cef- tazidime, which contains an attached propionic acid to O-ethyl oxime; ceftibuten, which contains a but-3-enoic acid moiety in place of the formaldehyde O-methyl oxime moiety; and cefcapene, which contains a but-1-en-1-yl moiety in place of the formaldehyde O-methyl oxime group.eThis grouping contains a 2-methylthiophene core, except for cefoxitin, which also contains a 7-methoxy group on the b-lactam ring.fThis grouping contains a (E)-5-amino-1,2,4-thiadiazole-3-carbaldehyde O-methyl oxime core except for ceftobiprole, which contains O-methyl oxime replaced with oxime; ce?uprenam, which contains O-methyl oxime replaced with O-?uoromethyl oxime; and ceftaroline fosamil, which contains the (E)-5-amino- group replaced with a (E)-5- phosphonoamino- group and the O-methyl oxime replaced with a O-ethyl oxime group.gThis grouping contains a 1-methyl-1H-tetrazole core.Nonirritating concentrations of cephalosporins to be used for drug testing. PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Kb2ludCBUYXNrIEZvcmNlIG9uIFByYWN0aWNlPC9BdXRo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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Kb2ludCBUYXNrIEZvcmNlIG9uIFByYWN0aWNlPC9BdXRo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ADDIN EN.CITE.DATA (2) TREATMENT OF THE ACUTE REACTIONAn impending generalized reaction to immediate hypersensitivity skin testing is unusual. However, this may be anticipated if patient has a sensation of throat irritation, seems apprehensive, is pale, has a rapid heartbeat, breaks out with perspiration, complains of weakness or faint feeling, nasal/ocular symptoms, appears flushed or has increased rate of respiration. If patient displays systemic/anaphylactic symptoms: Rapid onset: Have patient lie down Take blood pressure (do not inflate cuff over skin test site!) and pulse administer epinephrine; explain effects of epinephrine to patient (palpitations, shakiness, etc.)Gradual onset:Have patient lie down Take blood pressure (do not inflate cuff over injection site!) and pulse Notify physicianHave immediate access to emergency medicationsThe following supplies and reagents must be readily available:-Stethoscope and sphygmomanometer.-Tourniquet, syringes, and hypodermic needles.-Epinephrine 1:1000 for IM administration.-Oxygen with nasal cannula/mask.-Intravenous fluids.-Oral airway and large bore (16 + 14-gauge) needles.-Diphenhydramine (for IM or IV injection)-Cetirizine (oral)- Glucagon for injection-Solumedrol 125 mgNOTE: Hospital admission is required for poor response or lack of resolution of anaphylactic episode with the above measures.==============================================================Nursing Instructions PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5CZXJuc3RlaW48L0F1dGhvcj48WWVhcj4yMDA4PC9ZZWFy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==
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5CZXJuc3RlaW48L0F1dGhvcj48WWVhcj4yMDA4PC9ZZWFy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==
ADDIN EN.CITE.DATA (1)EQUIPMENT AND SUPPLIES: REAGENTS FOR PENICILLIN SKIN TESTING:Penicillin G (1,000,000 unit vial or 5,000,000 unit vial)Pre-Pen (benzylpenicilloyl polylysine) --full strengthPositive Control: Histamine Percutaneous: histamine base 6 mg/ml (histamine dihydrochloride 10 mg/ml) Intradermal: histamine base 0.1 mg/ml (histamine phosphate 0.275 mg/ml)Negative Control: Sodium chloride solution without preservative REAGENTS FOR OTHER ANTIBIOTIC SKIN TESTINGAmpicillin Sodium 1 gram, 500 mg, or 250 mgCefuroxime (Zinacef) 750 mg vial [second-generation cephalosporin]Cefazolin Sodium (Kefzol)1 gram vial [first generation]Ceftriaxone?(Rocephin)?500 mg vial [third generation]Cefotaxime Sodium (Claforan) 1 gram vial [third generation]ANTIBIOTICS FOR ORAL CHALLENGEAmoxicillin 250 mg tablet or 125 mg/5 ml oral suspensionPenicillin V potassium 250 mg tablet or 125 mg/5 ml oral solutionCefuroxime axetil (Ceftin) 125 or 250 mg tablet or 125 mg/5 ml oral suspension [2nd generation cephalosporin]Ceftibuten?(Cedax)?200 mg capsule or 90 mg/5 ml oral suspension: closest drug to use for oral challenge following skin testing with ceftriaxone [3rd generation cephalosporin]There are no oral forms of Cefazolin or Cefotaxime for oral challengeEQUIPMENT NEEDEDTimerMarkerPercutaneous skin test needles Alcohol soaked cotton or gauze Intradermal skin test syringesAlcohol swabs10 ml sterile vialsSterile water for injection (no preservative) for dilutionNormal saline (Sodium chloride) for injection (no preservative) for dilutionSyringes for mixing dilutionsFilter needle with micron filter (to draw up Prepen from ampule)RECONSTITUTIONA.Penicillin G 1,000,000 Units Shake well between dilutions.1. Reconstitute PEN G 1,000,000 U with sterile water (no preservative) according to manufacturer’s instructions to make a dilution of 100,000 U/ml. This dilution expires in one week when refrigerated. Label vial with medication name, strength, manufacturer, lot number, expiration date of the stock vial, diluent used and volume, ADDIN EN.CITE <EndNote><Cite><Author>Iammatteo</Author><Year>2014</Year><RecNum>63</RecNum><DisplayText>(12)</DisplayText><record><rec-number>63</rec-number><foreign-keys><key app="EN" db-id="dpd5evzzzszrr4esrwtx0tfgsttxzp2pfp5t" timestamp="1432226754">63</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Iammatteo, M.</author><author>Blumenthal, K. G.</author><author>Saff, R.</author><author>Long, A. A.</author><author>Banerji, A.</author></authors></contributors><auth-address>Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Mass. Electronic address: miammatteo@.
Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Mass.</auth-address><titles><title>Safety and outcomes of test doses for the evaluation of adverse drug reactions: a 5-year retrospective review</title><secondary-title>J Allergy Clin Immunol Pract</secondary-title><alt-title>The journal of allergy and clinical immunology. In practice</alt-title></titles><periodical><full-title>J Allergy Clin Immunol Pract</full-title><abbr-1>The journal of allergy and clinical immunology. In practice</abbr-1></periodical><alt-periodical><full-title>J Allergy Clin Immunol Pract</full-title><abbr-1>The journal of allergy and clinical immunology. In practice</abbr-1></alt-periodical><pages>768-74</pages><volume>2</volume><number>6</number><dates><year>2014</year><pub-dates><date>Nov-Dec</date></pub-dates></dates><isbn>2213-2201 (Electronic)</isbn><accession-num>25439369</accession-num><urls><related-urls><url>;(12)and expiration date/time after reconstitution. The remaining PEN G 100,000 U/ml can be divided into 10 ml sterile vials and frozen for future use. Frozen vials expire in 1 month. Once thawed, they expire in 1 week, and need to be relabeled to indicate the new expiration.2. If necessary, thaw above dilution. Add 0.5 ml of 100,000 U/ml PEN G to 4.5 ml normal saline for injection (no preservative) in a sterile 10 ml vial. This will equal 10,000 U/ml. The expiration is 12 hours after mixing. Label vial with medication name, strength, manufacturer, lot number, expiration date of the stock vial, diluent used and volume, and expiration date/time after reconstitution. Keep refrigerated. *This dilution is used for testing (prick and intradermal).B. Penicillin G 5,000,000 Units ReconstitutionShake well between dilutions.1.Reconstitute PEN G 5,000,000 U with sterile water for injection (no preservative) according to manufacturer’s instructions to make a dilution equal to 1,000,000 U/ml. The expiration is one week. Label vial with medication name, strength, manufacturer, lot number, expiration date of the stock vial, diluent used and volume, and expiration date/time after reconstitution. Keep refrigerated.2.Add 0.5 ml of 1,000,000 U/ml PEN G to 4.5 ml normal saline for injection (no preservative) in a sterile 10 ml vial. This will equal 100,000 U/ml. This dilution expires in one week when refrigerated. Label vial with medication name, strength, manufacturer, lot number, expiration date of the stock vial, diluent used and volume, and expiration date/time after reconstitution. Additional PEN G 100,000 U/ml can be prepared in 10 ml sterile vials and frozen for future use. Frozen vials expire in 1 month. Once thawed, they expire in 1 week, and need to be relabeled to indicate the new expiration.3.Add 0.5 ml of 100,000 U/ml PEN G to 4.5 ml normal saline for injection (no preservative) in sterile 10 ml vial. This will equal 10,000 U/ml. Expiration is 12 hours after mixing. Label vial with medication name, strength, manufacturer, lot number, expiration date of the stock vial, diluent used and volume, and expiration date/time after reconstitution. Keep refrigerated. *This dilution is used for testing (prick and intradermal).C. Ampicillin SodiumShake well between dilutions.Dilute 1 gram, 500 mg, or 250 mg ampicillin with sterile water (no preservative) according to manufacturer’s instructions to make a 500 mg/ml stock solution. Label vial with medication name, strength, manufacturer, lot number, expiration date of the stock vial, diluent used and volume, and expiration date/time after reconstitution. Keep refrigerated. The expiration is 4 days.As an example of making a 100 mg/ml ampicillin solution, dilute 1 ml of stock solution (ampicillin 500 mg/ml) with 4 ml of normal saline (no preservatives) in sterile 10 ml vial. This will equal 100 mg/ml. Expiration is 12 hours after mixing. Label vial with medication name, strength, manufacturer, lot number, expiration date of the stock vial, diluent used and volume, and expiration date/time after reconstitution. Keep refrigerated.Dilute 1 ml of 100 mg/ml ampicillin with 4 ml of normal saline (no preservatives) in sterile 10 ml. vial. This will equal 20 mg/ml. Expiration is 12 hours after mixing. Label vial with medication name, strength, manufacturer, lot number, expiration date of the stock vial, diluent used and volume, and expiration date/time after reconstitution. Keep refrigerated. *This dilution is used for testing (prick and intradermal).Prick testing is done first with the testing dilution (20 mg/ml). A sodium chloride (no preservative) negative control and a histamine phosphate control are also applied.If the prick test is negative, proceed with the intradermal testing to the same testing dilution (20 mg/ml) by injecting 0.02 – 0.03 ml intradermally along with the negative and positive controls.D.Cefuroxime (Zinacef) 750 mg vial Shake well between dilutions.Dilute Cefuroxime 750 mg vial with 7.5 ml of sterile water for injection (no preservative). This will equal 100 mg/ml stock solution. The expiration is 4 days. Label vial with medication name, strength, manufacturer, lot number, expiration date of the stock vial, diluent used and volume, and expiration date/time after reconstitution. Keep refrigerated.Dilute 1.0 ml of Cefuroxime 100 mg/ml with 9.0 ml of normal saline for injection (no preservatives) in sterile 10 ml vial. The expiration is 12 hours. This will equal 10 mg/ml. Label vial with medication name, strength, manufacturer, lot number, expiration date of the stock vial, diluent used and volume, and expiration date/time after reconstitution. Keep refrigerated. * This dilution is used for testing (prick and intradermal)Prick testing is done first using the 10 mg/ml dilution. A sodium chloride control and a histamine phosphate control are also applied.If prick test is negative, then proceed with intradermal testing with the same testing dilution (10 mg/ml), injecting 0.02 – 0.03 ml. intradermally, along with the negative and positive controls.E.Cefazolin Sodium Shake well between dilutions.Dilute Cefazolin 1 gm with 9.6 ml of sterile water for injection (no preservative). This will equal 100 mg/ml stock solution. The expiration is 4 days. Label vial with medication name, strength, manufacturer, lot number, expiration date of the stock vial, diluent used and volume, and expiration date/time after reconstitution. Keep refrigerated.Dilute 0.6 ml of Cefazolin 100 mg/ml with 2.4 ml of normal saline for injection (no preservatives) in sterile 10 ml vial. The expiration is 12 hours. This will equal 20 mg/ml. Label vial with medication name, strength, manufacturer, lot number, expiration date of the stock vial, diluent used and volume, and expiration date/time after reconstitution. Keep refrigerated. * This dilution is used for testing (prick and intradermal)Prick testing is done first using the 20 mg/ml dilution. A sodium chloride control and a histamine phosphate control are also applied.If prick test is negative, then proceed with intradermal testing with the same testing dilution (20 mg/ml), injecting 0.02 – 0.03 ml. intradermally, along with the negative and positive controlsF.Ceftriaxone (Rocephin) 500 mg vial Shake well between dilutions.Dilute Ceftriaxone 500 mg vial with 4.8 ml of sterile water for injection (no preservative). This will equal 100 mg/ml stock solution. The expiration is 10 days refrigerated. Label vial with medication name, strength, manufacturer, lot number, expiration date of the stock vial, diluent used and volume, and expiration date/time after reconstitution. Keep refrigerated.Dilute 1.0 ml of Ceftriaxone 100 mg/ml with 9.0 ml of normal saline for injection (no preservatives) in sterile 10 ml vial. The expiration is 12 hours. This will equal 10 mg/ml. Label vial with medication name, strength, manufacturer, lot number, expiration date of the stock vial, diluent used and volume, and expiration date/time after reconstitution. Keep refrigerated. * This dilution is used for testing (prick and intradermal)Prick testing is done first using the 10 mg/ml dilution. A sodium chloride control and a histamine phosphate control are also applied.If prick test is negative, then proceed with intradermal testing with the same testing dilution (10 mg/ml), injecting 0.02 – 0.03 ml. intradermally, along with the negative and positive controls.G. Cefotaxime Sodium (Claforan)Shake well between dilutions.Dilute 1 gm Cefotaxime with 9.5 ml sterile water (no preservative). This will equal 100 mg/ml stock solution. The expiration time is 4 days. Label vial with medication name, strength, manufacturer, lot number, expiration date of the stock vial, diluent used and volume, and expiration date/time after reconstitution. Keep refrigerated.Dilute 1ml of 100 mg/ml Cefotaxime with 9 ml normal saline (no preservative) in sterile 10 ml vial. This will equal 10 mg/ml stock solution. The expiration is 12 hours. Label vial with medication name, strength, manufacturer, lot number, expiration date of the stock vial, diluent used and volume, and expiration date/time after reconstitution. Keep refrigerated. *This dilution is used for testing (prick and intradermal). Prick testing is done first with the testing dilution (10 mg/ml), also applying a sodium chloride (no preservative) control and a histamine phosphate control.4.If the prick test is negative, proceed with the intradermal testing to the same testing dilution (10 mg/ml), by injecting 0.02 – 0.03 ml intradermally, along with the negative and positive controls.REFERENCES ADDIN EN.REFLIST 1. Bernstein IL, Li JT, Bernstein DI, Hamilton R, Spector SL, Tan R, et al. Allergy diagnostic testing: an updated practice parameter. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2008;100(3 Suppl 3):S1-148.2. Joint Task Force on Practice P, American Academy of Allergy A, Immunology, American College of Allergy A, Immunology, Joint Council of Allergy A, et al. Drug allergy: an updated practice parameter. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2010;105(4):259-73.3. Sullivan TJ. Advances in the diagnosis and management of penicillin allergy. N Engl Reg Allergy Proc. 1985;6(2):160-5.4. Blanca M, Romano A, Torres MJ, Fernandez J, Mayorga C, Rodriguez J, et al. Update on the evaluation of hypersensitivity reactions to betalactams. Allergy. 2009;64(2):183-93.5. Padial A, Antunez C, Blanca-Lopez N, Fernandez TD, Cornejo-Garcia JA, Mayorga C, et al. Non-immediate reactions to beta-lactams: diagnostic value of skin testing and drug provocation test. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2008;38(5):822-8.6. Green GR, Rosenblum AH, Sweet LC. Evaluation of penicillin hypersensitivity: value of clinical history and skin testing with penicilloyl-polylysine and penicillin G. A cooperative prospective study of the penicillin study group of the American Academy of Allergy. The Journal of allergy and clinical immunology. 1977;60(6):339-45.7. del Real GA, Rose ME, Ramirez-Atamoros MT, Hammel J, Gordon SM, Arroliga AC, et al. Penicillin skin testing in patients with a history of beta-lactam allergy. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2007;98(4):355-9.8. Macy E, Contreras R. Health care use and serious infection prevalence associated with penicillin "allergy" in hospitalized patients: A cohort study. The Journal of allergy and clinical immunology. 2014;133(3):790-6.9. Hypersensitivity PTiD. Drug Hypersensitivity. Immunology and Allergy Clinics of North America. 29: W.B. Saunders Company; 2009.10. Kelkar PS, Li JT. Cephalosporin allergy. N Engl J Med. 2001;345(11):804-9.11. Saxon A, Beall GN, Rohr AS, Adelman DC. Immediate hypersensitivity reactions to beta-lactam antibiotics. Annals of internal medicine. 1987;107(2):204-15.12. Iammatteo M, Blumenthal KG, Saff R, Long AA, Banerji A. Safety and outcomes of test doses for the evaluation of adverse drug reactions: a 5-year retrospective review. The journal of allergy and clinical immunology In practice. 2014;2(6):768-74.13. Pichichero ME, Zagursky R. Penicillin and cephalosporin allergy. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2014;112(5):404-12. ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related searches
- american college of education scam
- american college of surgery
- american college of neurology
- american college of neurology guidelines
- american college of epi
- american college of insurance
- american college of financial planning
- american college of education employment
- american college of functional neurology
- american college of surgeons
- fellow american college of surgeons
- american college of surgeons abbreviation